- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
The supercomputing genomics engine, a decade in the making, has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with multiple tumor types—and with the world's largest database of human cancer whole genomes—enabled the discovery of novel neoepitopes in cancer tissue for the development of neoepitope antibodies and vaccines in the war against cancer
Health systems ordering GPS Cancer, including
WHAT: |
Panel discussion and press conference with
|
||
-- Advancements in immunotherapy enabled by GPS Cancer to advance molecular science, which provide oncologists with unprecedented insights to help identify personalized, cost-effective therapy strategies before treatment begins. |
|||
-- How the studies can further the development and understanding of novel neoepitope antibodies, and their role in finally achieving low toxicity, targeted cancer therapy—with the ultimate hope of cancer antibodies or vaccines. |
|||
-- The role of machine learning in the complex understanding of the cancer genome and how NantWork’s Medical Reasoning Engine provides real-time predictive modeling and clinical outcomes that can continually improve physicians’ ability to make more effective care decisions. |
|||
-- How these initiatives can help address the new requirements of
the |
|||
WHO: |
-- Dr.
|
||
-- |
|||
-- |
|||
-- Dr.
|
|||
-- Dr.
|
|||
-- Dr.
|
|||
-- |
|||
WHEN: |
|
||
WHERE: |
Horizon Blue Cross Blue |
||
|
|||
|
|||
Members of the media must RSVP to
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients, as
well as our contribution to the Cancer 2020 initiative. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially from
management’s current expectations include, among other things, that GPS
Cancer may not perform as anticipated, that sufficient physicians may
not adopt GPS Cancer to assist their diagnoses or that healthcare payers
may not provide reimbursement for GPS Cancer as expected. Our business
is subject to numerous additional risks and uncertainties, including,
among others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities; our
planned sales, marketing, and research and development activities;
unanticipated increases in costs or expenses; and risks associated with
international operations. Information on these and additional risks,
uncertainties, and other information affecting our business and
operating results can be found in our existing and future filings with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. We disclaim any obligation to update
these forward-looking statements except as may be required by law.
About NantHealth, Inc.
About GPS Cancer™
GPS Cancer™ is a unique, molecular profile
analysis available through
About
About
COTA is the health care informatics and
precision analytics company that builds research-grade, real-world data
to exponentially improve outcomes, reduce cost and ensure the right care
for the right patient every time. The patented COTA Nodal Address System
(CNA) is the first and only digital classification system that
transforms prognostically significant variables into a digital code --
precisely categorizing patient factors, their diseases and intended
therapies to measure treatment outcomes, identify variances in care and
enable quality benchmarking, research, discovery and the transition to
value-based medicine. For more information, please visit www.oncota.com.
COTA - Best Care Made Clear.™
View source version on businesswire.com: http://www.businesswire.com/news/home/20161026006031/en/
or
Kevin_McArdle@HorizonBlue.com
Source: